Top Factor Driving Non-Insulin Therapies For Diabetes Market Growth in 2025: Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic

How Big Is the Non-Insulin Therapies For Diabetes Market Expected to Be, and What Will Its Growth Rate Be?
The market size for non-insulin diabetes therapies has substantially expanded in the past few years. The market, which was worth $19.98 billion in 2024, is projected to surge to $21.41 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. The noticeable growth during the historical period can be tied back to the heightened prevalence of diabetes, increased knowledge about diabetes treatment, a spike in healthcare spending, lifestyle alterations leading to greater incidence rates, a rise in diagnoses, enhanced government endeavors for diabetes management, and a boost in pharmaceutical research and development investment.

Expectations are high for the non-insulin diabetes therapies market, with strong growth anticipated over the next several years. Predicted to reach $27.9 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 6.8%, various factors contribute to this expected growth. Among these are increased rates of diabetes, heightened awareness surrounding diabetes management, the growing use of combination therapies, a rising elderly population, an increase in healthcare expenses, the extension of telemedicine, and a shifted preference towards oral medications. In the upcoming years, the major trends to watch for are advancements in both oral and injectable medicines, improvements in drug delivery systems and oral peptide delivery, increased use of telemedicine and digital health solutions, and continued progress in combination therapies.

What Are the Main Catalysts for Growth in the Non-Insulin Therapies For Diabetes Market?
The rise in diabetes cases is anticipated to spur the expansion of non-insulin treatments in the diabetes market. Diabetes, a chronic health problem characterized by elevated levels of blood sugar, results from the body's inability to produce sufficient insulin or adequately utilize the insulin it has. The rising incidence of diabetes can be attributed to inactive lifestyles, poor diet habits, genetic factors, aging populations, obesity, ethnic factors, lack of knowledge, inadequate access to healthcare, and environmental aspects. Non-insulin diabetes treatments aim to manage the disease by enhancing insulin receptiveness, minimizing liver glucose production, boosting glucose absorption in muscle cells, and improving overall blood sugar control. As an illustration, The British Diabetic Association reported in April 2023 that 4.3 million people in the UK had been diagnosed with diabetes. Registration records from 2021-22 indicate an increase of 148,951 cases relative to 2020-21. Moreover, over 2.4 million UK residents are at a significant risk of contracting type 2 diabetes. Consequently, the growing prevalence of diabetes is fuelling the expansion of non-insulin treatments in the diabetes market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

Who Are the Dominant Companies Influencing Non-Insulin Therapies For Diabetes Market Trends?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

How Is the Non-Insulin Therapies For Diabetes Market Evolving?
Leading enterprises in the non-insulin diabetes therapies marketplace are focusing on the development of tailor-made diabetes oversight systems to improve patient results via live tracking, interpreting data and personalizing treatment approaches. Such bespoke diabetes management systems modify care and supervision according to the specific requirements of each patient, exploiting real-time data analysis to optimize healthcare and outcomes. For example, in November 2022, Eli Lilly and Company, an American pharmaceutical company, introduced the Tempo tailor-made diabetes management system. This platform consists of three key parts: the Tempo Smart Button, the TempoSmart application, and the preloaded insulin pen known as the Tempo Pen. These elements work together to offer customized advice to adults suffering from diabetes. This innovative platform is engineered to aid adults with diabetes type 1 or 2, and their medical practitioners, in making well-informed, evidence-based treatment choices using Lilly insulins.

What Are the Different Segmentations in the Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetes market covered in this report is segmented -

1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione's, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications

Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Which Region Is at the Forefront of the Non-Insulin Therapies For Diabetes Market?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Non-Insulin Therapies For Diabetes Global Market Report?

- Market Size Analysis: Analyze the Non-Insulin Therapies For Diabetes Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Non-Insulin Therapies For Diabetes Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Non-Insulin Therapies For Diabetes Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Non-Insulin Therapies For Diabetes Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.